Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: A preliminary randomized study

Probiotic supplementation improves glycemic control in persons with diabetes and the current study examined whether these benefits extend to healthy individuals. The current study was a 90-day placebo-controlled, double-blind, randomized clinical trial of Lactobacillus rhamnosus GG in healthy middle-aged and older adults. Fasting blood glucose and HbA1c were quantified at baseline and follow up. ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group. If replicated, Lactobacillus rhamnosus GG may protect against changes in glycemic control. •Middle age and older adults consumed Lactobacillus rhamnosus GG or placebo for 90 days in a randomized clinical trial.•HbA1c levels were stable in those randomized to probiotic supplementation, but significantly increased in placebo controls.•If replicated, supplementation with Lactobacillus rhamnosus GG may help in management of hyperglycemic states.